A Comprehensive Retrospective Cohort Study of the Journey of B-cell Lymphoma in Taiwan

Overview

Journal Sci Rep

Specialty Science

Date 2021 May 13

PMID 33980914

Citations 2

Authors

Sung-Nan Pei

Ming-Chung Wang

Ming-Chun Ma

Ching-Yuan Kuo

Chun-Kai Liao

Hong Qiu

Lee Anne Rothwell

Yanfang Liu

Affiliations

Soon will be listed here.

Abstract

Complete disease journey and risk factors for poor outcomes are needed to facilitate effectiveness evaluations of new therapies and clinical decision-making in B-cell Non-Hodgkin lymphoma (B-NHL), particularly in Asia where such data are lacking. This retrospective cohort study used electronic medical records from a regional medical centre in southern Taiwan to follow-up 441 patients newly diagnosed with common B-NHL subtypes: Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), Chronic Lymphocytic Leukaemia/Small Lymphocytic Lymphoma (CLL/SLL), Marginal Zone Lymphoma (MZL), Mantle Cell Lymphoma (MCL), and Waldenström macroglobulinemia (WM), between 01-Jan-2008 and 31-Dec-2013, until 31-Dec-2017. Treatment pathways were modelled using a Markov approach. Stage III/IV disease at diagnosis was frequent for patients with DLBCL, FL, MCL and WM. Hepatitis B surface antigen/hepatitis C virus seropositivity was 18.6%/12.3%. Clinical responses to 1st-line treatment were observed in 76.0% (DLBCL), 87.3% (FL), 86.0% (MZL), 60.0% (MCL), and 42.9% (WM) of patients. For DLBCL, disease control was achieved by ~ 50% after 1st-line, ~ 24% after 2nd-line, ~ 17% after 3rd-line. Patients with Stage III/IV DLBCL or age > 65 years at diagnosis had lower rates of active treatment, poorer disease control and higher mortality than patients with early stage disease or age ≤ 65 years. Disease flare < 6 months after 1st-line treatment was significantly associated with mortality. Despite good clinical response rates for some sub-types, survival remains poor. New treatments are needed to improve the outcome of B-NHL.

Citing Articles

High G9a Expression in DLBCL and Its Inhibition by Niclosamide to Induce Autophagy as a Therapeutic Approach.

Hsu C, Chang K, Chuang T, Chu M, Lin P, Liu H Cancers (Basel). 2023; 15(16).

PMID: 37627178 PMC: 10452841. DOI: 10.3390/cancers15164150.

PET-Based Staging Is Cost-Effective in Early-Stage Follicular Lymphoma.

Lo A, James L, Prica A, Raymakers A, Peacock S, Qu M J Nucl Med. 2021; 63(4):543-548.

PMID: 34413148 PMC: 8973292. DOI: 10.2967/jnumed.121.262324.

References

Salles G, Barrett M, Foa R, Maurer J, OBrien S, Valente N . Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience. Adv Ther. 2017; 34(10):2232-2273. PMC: 5656728. DOI: 10.1007/s12325-017-0612-x. View

Huang C, Yang Y, Chen Y, Chang J, Chen K, Lu C . The impact of hepatitis B virus infection and vaccination on the development of non-Hodgkin lymphoma. J Viral Hepat. 2017; 24(10):885-894. DOI: 10.1111/jvh.12713. View

Modvig L, Vase M, DAmore F . Clinical and treatment-related features determining the risk of late relapse in patients with diffuse large B-cell lymphoma. Br J Haematol. 2017; 179(1):75-82. DOI: 10.1111/bjh.14822. View

Bassig B, Au W, Mang O, Ngan R, Morton L, Ip D . Subtype-specific incidence rates of lymphoid malignancies in Hong Kong compared to the United States, 2001-2010. Cancer Epidemiol. 2016; 42:15-23. DOI: 10.1016/j.canep.2016.02.007. View

Perry A, Diebold J, Nathwani B, Maclennan K, Muller-Hermelink H, Bast M . Non-Hodgkin lymphoma in the developing world: review of 4539 cases from the International Non-Hodgkin Lymphoma Classification Project. Haematologica. 2016; 101(10):1244-1250. PMC: 5046654. DOI: 10.3324/haematol.2016.148809. View

Ferreri A, Ernberg I, Copie-Bergman C . Infectious agents and lymphoma development: molecular and clinical aspects. J Intern Med. 2009; 265(4):421-38. DOI: 10.1111/j.1365-2796.2009.02083.x. View

Coiffier B, Thieblemont C, Van den Neste E, Lepeu G, Plantier I, Castaigne S . Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. Blood. 2010; 116(12):2040-5. PMC: 2951853. DOI: 10.1182/blood-2010-03-276246. View

Chen C, Huang K, Shen J, Tsao K, Huang Y . A large-scale seroprevalence of Epstein-Barr virus in Taiwan. PLoS One. 2015; 10(1):e0115836. PMC: 4304788. DOI: 10.1371/journal.pone.0115836. View

Biagi J, Seymour J . Insights into the molecular pathogenesis of follicular lymphoma arising from analysis of geographic variation. Blood. 2002; 99(12):4265-75. DOI: 10.1182/blood.v99.12.4265. View

10.

Chen C, Yang P, Huang G, Lee H, Sung J, Sheu J . Estimation of seroprevalence of hepatitis B virus and hepatitis C virus in Taiwan from a large-scale survey of free hepatitis screening participants. J Formos Med Assoc. 2007; 106(2):148-55. DOI: 10.1016/S0929-6646(09)60231-X. View

11.

Herrera A . Noncellular Immune Therapies for Non-Hodgkin Lymphoma. Hematol Oncol Clin North Am. 2019; 33(4):707-725. DOI: 10.1016/j.hoc.2019.03.007. View

12.

Casulo C, Byrtek M, Dawson K, Zhou X, Farber C, Flowers C . Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study. J Clin Oncol. 2015; 33(23):2516-22. PMC: 4879714. DOI: 10.1200/JCO.2014.59.7534. View

13.

Chen C, Yang J, Lin S, Sun C, Bai C, You S . Slow decline of hepatitis B burden in general population: Results from a population-based survey and longitudinal follow-up study in Taiwan. J Hepatol. 2015; 63(2):354-63. DOI: 10.1016/j.jhep.2015.03.013. View

14.

Smith A, Crouch S, Lax S, Li J, Painter D, Howell D . Lymphoma incidence, survival and prevalence 2004-2014: sub-type analyses from the UK's Haematological Malignancy Research Network. Br J Cancer. 2015; 112(9):1575-84. PMC: 4453686. DOI: 10.1038/bjc.2015.94. View

15.

Armitage J, Gascoyne R, Lunning M, Cavalli F . Non-Hodgkin lymphoma. Lancet. 2017; 390(10091):298-310. DOI: 10.1016/S0140-6736(16)32407-2. View

16.

Cheson B, Pfistner B, Juweid M, Gascoyne R, Specht L, Horning S . Revised response criteria for malignant lymphoma. J Clin Oncol. 2007; 25(5):579-86. DOI: 10.1200/JCO.2006.09.2403. View

17.

Hamadani M, Hari P, Zhang Y, Carreras J, Akpek G, Aljurf M . Early failure of frontline rituximab-containing chemo-immunotherapy in diffuse large B cell lymphoma does not predict futility of autologous hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2014; 20(11):1729-36. PMC: 4194275. DOI: 10.1016/j.bbmt.2014.06.036. View

18.

Matsuo K, Kusano A, Sugumar A, Nakamura S, Tajima K, Mueller N . Effect of hepatitis C virus infection on the risk of non-Hodgkin's lymphoma: a meta-analysis of epidemiological studies. Cancer Sci. 2004; 95(9):745-52. PMC: 11159764. DOI: 10.1111/j.1349-7006.2004.tb03256.x. View

19.

Lee M, Tan T, Feng A, Liu M . Clinicopathological analysis of 598 malignant lymphomas in Taiwan: seven-year experience in a single institution. Am J Hematol. 2006; 81(8):568-75. DOI: 10.1002/ajh.20649. View

20.

Li S, Young K, Medeiros L . Diffuse large B-cell lymphoma. Pathology. 2017; 50(1):74-87. DOI: 10.1016/j.pathol.2017.09.006. View